Sun Pharma Q3 Results: US formulation sales miss expectations but margin expands

Share it

Adjusted for a forex gain, the Sun Pharma’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at ₹4,192 crore, a growth of 25% from last year’s figure of ₹3,353 crore. The base quarter had a forex loss of ₹124 crore.

Leave a Comment

Your email address will not be published. Required fields are marked *